top of page

Research

IMG_2427.jpg

As Professor of Urology at UCL I lead a multidisciplinary research team. In 2021 I was awarded the prestigious Royal College of Surgeons of England Research Consultant Research fellowship. I am actively involved in clinical research and has published extensively. I maintain a strong academic interest and leads on several high profile research projects. Click here for my researchgate profile

dNeuroSAFE Proof prostate cance study logo

I am  Chief investigator for the NeuroSAFE PROOF study. This is funded through the National Institute for Health Research - Research for Patient Benefit scheme and the JP Moulton Foundation. The study is a randomised controlled study to evaluate a new technique called NeuroSAFE.

​I am  the Chief Investigator of the PROVENT clinical trial. This trial will evaluate the role of aspirin and vitamin D in preventing progression of indolent prostate cancer, to more sinister disease. The study is well received by men on active surveillance with a high rate of uptake by those who are eligible as it allows those men to feel that they are doing something rather than just waiting and seeing if their cancer will progress. This exemplifies my preference for doing surgery only when it is necessary. The feasibility phase of the study is now complete.​​​​​​​

​​​

Prostate cancer is one of the most common cancers but can often be cured with surgery. Sadly, this sometimes leads to a loss of erections, because the nerves that bring about the erections run in the outer part of the prostate. A process known as nerve sparing, where the outer layers of the prostate are peeled off the prostate, increases the chance of men being potent after surgery. On the other hand, nerve sparing increases the risk of cancer being left behind. Any cancer left behind will need more treatment with radiotherapy that will leave men without the ability to achieve erection, even if they had nerve-sparing surgery.

 

The prostate is enclosed by a capsule that contains smooth muscle and nerves. Many men having their prostates removed have cancer that extends through the capsule of the prostate. Currently, there isn’t a good way of knowing whether the cancer has spread through the capsule of the prostate and the accuracy of scans like MRI in detecting capsular involvement is limited. Nerve sparing surgery in these patients can cause some cancer to be left behind. A new technique called NeuroSAFE technique may address this problem. It includes a step where a doctor looks at the prostate near where the nerves were, to check for exposed cancer. If cancer is found at the edge of the prostate, the nerve tissue is removed so the chance of the cancer coming back is the same as when cancer cells are not exposed.

 

We are now actively recruiting to a  large-scale trial where NeuroSAFE will be compared with the current UK practice for prostate cancer (nerve sparing based on an MRI scan, biopsy results and the way the prostate feels).

Provent prostate cancer study logo

Book an appointment

For further advice on urological problems including cancer, please call us on +44 07841034453 to book an appointment, with Mr. Greg Shaw at his private clinic in London. Alternatively, contact us online.

  1. The LaserSAFE feasibility trial, a prospective blinded evaluation of LaserSAFE versus NeuroSAFE for real time margin assessment during radical prostatectomy R Almeida-Magana, E Dinneen, T Al-Hammouri, …, G Shaw Accepted BJUi 2025

  2. The cost-effectiveness of intraoperative margin assessment during radical prostatectomy. Joost N.H. van Drumpt…. M Sedelaar, G Shaw, D. Somford. Accepted BJUi Dec 2025

  3. Exploring the Link Between Obligate Anaerobe-Related Dysbiosis and Prostate Cancer Development: A Pilot Study. E Ladoukakis,,T Oliver..G Shaw, B Nedjai Cancers Nov 2025

  4. Barriers and Facilitators to Prostate Cancer Healthcare in Black Men in the UK: From Diagnosis to Survivorship – A Qualitative Study", H Mohammed, … Shaw G accepted Journal of cancer survivorship,2025

  5. Editorial- New technology presents alternative approaches for intraoperative margin evaluation and secondary resection at radical prostatectomy. Shaw G, Van Leeders G, Graefen M, Eur Urol 2025

  6. NeuroSAFE versus standard robot-assisted radical prostatectomy (NeuroSAFE PROOF): a randomised, controlled, patient-blinded, IDEAL stage 3 trial. E Dinneen, R Almeida-Magana, ……J Kelly, G Shaw, The Lancet Oncology 2025

  7. IP8-FLUORESCE: A prospective paired-cohort study evaluating the diagnostic accuracy of fluorescence confocal microscopy for real-time assessment of surgical margins in radical prostatectomy N Mayor, A Light, A Silvanto…G Shaw, ..M Winkler, Accepted Eur Urol 2025

  8. Prostate cancer diagnosis, classification and treatment overview. Shaw G & Almeida R, In Press, Surgery 2025

  9. Radical prostatectomy causes penile hypoxia and new plaque formation M Megson, J Zhang, S Bate, G Shaw, D Ralph & S Cellek, Journal of Sexual Medicine, 2025

  10. Endo-FASt3r:Endoscopic Foundation model Adaptation for Structure from motion. Zeinoddin M,…. Shaw G… Stoyanov D, proceedings of the Medical Image Computing and Computer Assisted Intervention – MICCAI 2025 Conference, Microsoft CMT 2025

  11. A Systematic Review of the Effects of Nerve Sparing during Radical Prostatectomy. G Busuttil, D Goh, G Shaw, .. R Galbraith, Malta Medical journal Vol. 37 No. 2 (2025)

  12. A systematic review and meta-analysis of the impact of preoperative surgical planning in robotic-assisted radical prostatectomy on trifecta outcomes. Accepted 2025. Day E, Tandogdu Z, …Shaw G. Minerva Urology and Nephrology

  13. CaNCaP03, Cambridge Neoadjuvant Cancer of the Prostate 03:” a Study into the Photoodynamic Biomarker Effects of Olaparib (a PARP inhibitor) ± Degarelix (a GnRH antagonist) given Prior to Radical Prostatectomy. Pacey S,….Shaw G, Clinical Cancer Research, Accepted for publication 2024

  14. A Systematic Review and Meta-analysis of the Impact of Pre-operative Surgical Planning in Robotic Assisted Radical Prostatectomy on Trifecta Outcomes, E Day…G Shaw, Z Tandogdu, Minerva Urology and Nephrology, Accepted for publication 2024

  15. Exploring the Link Between Obligate Anaerobe-Related Dysbiosis and Prostate Cancer Development: A Pilot Study E Ladoukakis ..G Shaw, B Nedjai. Cancers 2025, 17, 70

  16. Accuracy of the LaserSAFE technique for detecting positive surgical margins during robot-assisted radical prostatectomy: blind assessment and inter-rater agreement analysis- Almeida-Magana R.. Shaw G, Freeman A & Haider A, Histopathology 2024 Histopathology. 2025 Feb;86(3):433-440.

  17. Complete urethral preservation in robot-assisted radical prostatectomy: step-by-step description of surgical technique. Al-Hammouri T, Almeida-Magana R, Tzelves L, Al-Bermani O, Tandogdu Z, Ockrim J, Shaw G. BJU Int. 2024 Aug 27. doi: 10.1111/bju.16508. PMID: 39191387

  18. Intra-operative margin assessment during radical prostatectomy: frozen in time or ready for digital defrost? Dinneen E, ..Shaw G. Histopathology. 2024 Aug 5. doi: 10.1111/his.15290. PMID: 39104212 (image from paper used for front cover of histopathology journal special edition)

  19. Histological sampling protocols for transurethral resection of prostate specimens need reappraisal. M Varma…G Shaw… M Zhou, S Williamson accepted Histology 2024

  20. Urinary and Sexual Impact of Robotic Radical Prostatectomy: Reporting of Patient-reported Outcome Measures in the First Year after Radical Prostatectomy in a Contemporary Multicentre Cohort in the United Kingdom. J Bridge, MLabban .. CM. Moore, on behalf of the TrueNTH Post Surgery UK Investigators, European Urology Open Science, 64 (2024) 11–21

  21. Reply to Francesco Montorsi, Marco Moschini, Giuseppe Rosiello, Andrea Salonia, and Alberto Briganti’s Letter to the Editor re: Stamatios Katsimperis, Lazaros Tzelves, Zafer Tandogdu, et al. Complications After Radical Cystectomy: A Systematic Review... on May 08, 2024. Eur Urol focus 2024 PMID: 39403832

  22. Accuracy of Ex-vivo Fluorescence Confocal Microscopy in Margin Assessment of Solid Tumors: A Systematic Review, Almeida R..Shaw G, Journal of Histochemistry & Cytochemistry Accepted 2023

  23. Improving fluorescence confocal microscopy for margin assessment during RARP: The LaserSAFE technique. R Almeida-Magana, M Au, T Al-Hammouri, K Dinneen, A Haider, A Freeman, G Shaw, Accepted for publication PMID: 38009389. BJUi 2023

  24. Re: Multiparametric MRI is not sufficient for prostate cancer staging: A single institutional experience validated by a multi-institutional regional collaborative.   Urological Oncology: Seminars and Original Investigations 41 (2023) 355.e1-355.e8, E Dinneen, V Kasivisvanathan, F Giganti , C  Allen, G Shaw , S Punwani. Accepted for publication 2023

  25. RE: EURUROL-D-23-01005 Re: Freddie C. Hamdy, Jenny L. Donovan, J. Athene Lane, et al. Fifteen-Year Outcomes After Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 2023;388:1547–58, Shaw G, Roobol M, Kelly J. Eur Urol. Accepted 2023

  26. Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis, S Katsimperis, L Tzelves, ..G Shaw..A Skolarikos,European Urology Focus,2023,ISSN 2405-4569, https://doi.org/10.1016/j.euf.2023.05.002.

  27. Protocol for a Prospective Study Evaluating Circulating Tumour Cells Status to Predict Radical Prostatectomy Treatment Failure in Localised Prostate Cancer Patients (C-ProMeta-1) Al-Hammouri, T ..G Shaw BMC Cancer 23, 581 (2023). https://doi.org/10.1186/s12885-023-11081-0

  28. Rare primary prostate cancer presenting with testicular and hip pain. Lau M, Almeida R, Al- Hammouri T, MIscovic D, Haydar A, Shaw G, Lancet Oncol. 2023 Apr;24(4):e186. doi: 10.1016/S1470-2045(23)00002-5. PMID: 36990616.

  29. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metaststatic prostate cancer- CR Davies,.. G Shaw,.. YJ Lu Front Oncol. 2023 Jan 16;12:1060864. doi: 10.3389/fonc.2022.1060864. PMID: 36727071; PMCID: PMC9885040.

  30. Prostate Cancer (a review), Almeida R, Shaw GL, Accepted for publication, Surgery, Sept 2022

  31. Neurosafe proof: study protocol for a single blinded, IDEAL stage 3, multi-centre, randomised controlled trial of NEUROSAFE robotic- assisted radical prostatectomy versus standard robotic-assisted radical prostatectomy in men with localized prostate cancer. E Dinneen, ….GL Shaw. Trials. 2022 Jul 22;23(1):584. doi: 10.1186/s13063-022-06421-7. PMID: 35869497; PMCID: PMC9306247.

  32. Feasibility of aspirin and/or Vitamin D3 for men with prostate cancer on active surveillance with Prolaris testing, E Dinneen, …, G Shaw, J Cusick, BJUI Compass. 2022 Jun 11;3(6):458-465. doi: 10.1002/bco2.169. eCollection 2022 Nov. PMID: 36267207

  33. Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. Luszczak S, … Shaw G, .. Heavey S. Sci Rep. 2020 Sep 1;10(1):14380 PMID: 32873828

  34. E-Consent – a guide to maintain recruitment in clinical trials during the COVID-19 pandemic. R Almeida-Magana … G Shaw. Trials. 2022 May 12;23(1):388. doi: 10.1186/s13063-022-06333-6. PMID: 35550639;

  35. Negative mpMRI rules out extra-prostatic extension in prostate cancer before robot-assisted radical prostatectomy. E Dinneen…. GL Shaw*, S Punwani* Diagnostics (Basel). 2022 Apr 23;12(5):1057. doi: 10.3390/diagnostics12051057. PMID: 35626214. (* denotes equal contribution)

  36. Avoiding unnecessary biopsy after multiparametric prostate MRI with VERDICT analysis:  the INNOVATE study. S Singh, ..G Shaw… S Punwani, Radiology. 2022 Dec;305(3):623-630. doi: 10.1148/radiol.212536. Epub 2022 Aug 2. PMID: 35916679

  37. Histo-MRI map: A prospective cohort study mapping MRI to histology for biomarker validation and prediction of prostate cancer. S Singh,.., G Shaw,…,D Alexander, S Punwani BMJ Open Accepted 2022

  38. Current process and outcomes of the surgical management of LUTS due to benign prostatic enlargement – Results from the national Audit of Surgical Management of BPE (AuSuM BPE). by Joshi, Hr.. Shaw, Greg; .. Betts, Chris Scottish journal or Urology 2021 May;66(2):58-65 2021 PMID 33459189

  39. Re: Bernardo Rocco, Luca Sarchi, Simone Assumma et al.  Digital Frozen Sections with Fluorescence Confocal Microscopy During Robot-assisted Radical Prostatectomy: Surgical Technique. European Urology 2021 May 5;S0302-2838(21)00227-X.  doi: 10.1016/j.eururo.2021.03.021.   E Dinneen, J Oxley, G Shaw, and on behalf of the NeuroSAFE PROOF Team. European Urology 2021.

  40. Comparative effectiveness analysis of oncological and functional outcomes after salvage radical treatment with surgery or radiotherapy following primary focal or whole-gland ablative therapy for localised prostate cancer. A Nathan., G.Shaw.,.H Payne Clinical Oncology 2021Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e69-e78. Epub 2021 Nov 3. PMID: 34740477.

  41. New recommendations to reduce unnecessary blood tests following robot assisted radical prostatectomy. A Nathan ,…G Shaw .. , S Nathan  BJU Int  2021 Jun 10. PMID: 34110673

  42. Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial, F Giganti, .., G Shaw et al. European Radiology 2022 PMID 34327583 (GOLD AWARD- most cited paper in GU radiology 2023)

  43. Evaluation of the Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: Diagnostic Outcomes and Prostate Specific Antigen and Prostate Specific Antigen Density Values from the INNOVATE Trial H Pye, S Singh,.. G Shaw, ..H Whitaker accepted Cancers 2021 PMID 33924255

  44. Salvage Versus Primary Robot-assisted Radical Prostatectomy: A Propensity-matched Comparative Effectiveness Study from a High-volume Tertiary Centre Nathan A.., Shaw G, …Nathan S Eur Urol Open Science 2021 PMID 33997823

  45. Life of Pi- E Dinneen & G Shaw- BJU Int. 2020 Dec;126(6):754-755. PMID: 33270968

  46. Tandogdu Z.. Shaw G… Kelly J. Management of patients who opt for radical prostatectomy during the COVID-19 pandemic: An International Accelerated Consensus view. BJU Int. 2020 Nov 13. PMID: 33185026

  47. Major urological cancer surgery for patients is safe and surgical training should be encouraged during the COVID-19 pandemic: A multi-centre analysis of 30-day outcomes. Wei Shen Tan et al. Collaborator. Eur Urol Open Sci. 2021 Mar;25:39-43. PMID: 33458711

  48. The identification of plasma exosomal miR-423-3p as a potential predictive biomarker for prostate cancer castration-resistance development by plasma exosomal miRNA sequencing. Tianyu Guoa..Greg Shaw, et al. Front Cell Dev Biol. 2021 Jan 7;8:602493. PMID: 33490068

  49. A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site. A cohort study of 30 day mortality after NON-EMERGENCY surgery in a COVID-19 cold site. Kasivisvanathan, V...Wood, C. UCLH study group collaborators. International Journal of Surgery, 2020, 84, pp. 57-65 PMID: 33122153

  50. NeuroSAFE frozen section during robot-assisted radical prostatectomy (RARP): Peri-operative and Histopathological Outcomes from the NeuroSAFE PROOF Feasibility Randomised Controlled Trial. Eoin Dinneen, ..J Grierson, A Haider, A Freeman, and G Shaw. BJU Int. 2020 Sep 27. PMID: 32985121

  51. Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer L  Li , .., G Shaw, .. M Ladomery et al. Br J Cancer. 2020 Sep;123(6):1024-1032. PMID: 32581342

  52. Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins. B Rocco , ..G Shaw, S Nathan, S Micali , G Bianchi, A Maiorana , G Pellacani, R Montironi  BJU Int, 2020 Sep;126(3):336-338.  PMID: 32401370

  53. NeuroSAFE Technique - pathological considerations and practical implications to guide nerve-sparing surgery in prostate cancer patients. E Dinneen, A Hayder, GL Shaw, Histopathology. 2020 Oct;77(4):536-538. PMID: 32945017

  54. NeuroSAFE PROOF Randomised Controlled Feasibility Study:Brief Report of Perioperative outcomes, histological concordance and feasibility. E Dinneen, , GL Shaw Eur Urol. 2020 Sep;78(3):476-478. PMID: 32340693

  55. Intraoperative Frozen Section for margin evaluation during Radical Prostatectomy: A Systematic Review. Eoin Dinneen, MIchelle van der Slot, Kelvin Adasonla, Jin Tan, Jack Grierson, Aiman Haider, Alex Freeman, and Greg Shaw Eur Urol Focus. 2019 Nov 29. PMID: 31787570

  56. Re: Non-invasive detection of clinically significant prostate cancer using circulating tumor cells. Xu L, Mao X, Grey A, Scandura G, Guo T, Burke E, Marzec J, Abdu S, Stankiewicz E, Davies CR, Rajan P, Tipples K, Hines J, Chan PY, Campbell D, Wilkinson K, Kudahetti S, Shamash J, Oliver T, Berney D, Shaw G, Lu YJ. Reply by Authors. Journal of Urology, vol. 203, no. 1, 2020, pp. 73-82.

  57. Use of Magnetic Resonance Imaging (MRI) and biopsy data to guide sampling procedures for prostate cancer biobanking. S Heavey, A Haider, A Sridhar, H Pye, G Shaw, A Freeman, H Whitaker. J Vis Exp. 2019 Oct 10;(152). PMID: 31657791

  58. Thompson JE, …Shaw GL, et al. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. J Urol. 2019;201(6):1134-43.

  59. Re:”What is the role of NeuroSAFE in robotic radical prostatectomy?” Journal of Robotic surgery. Dinneen E,..Shaw GL J Robot Surg. 2019 Oct;13(5):707-708. PMID: 30980228

  60. Massive Ascites Following Robot-Assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: A Case Report Ahmed S, Shaw G, Alkadhi O 27 Jun 2019 https://doi.org/10.1089/cren.2018.0080

  61. Dinneen E, Haider A, Allen C, Freeman A, Briggs T, Nathan S, Brew-Graves C, Grierson J, Williams NR, Persad R, Oakley N, Adshead JM, Huland H, Haese A, Shaw  G. NeuroSAFE robot-assisted laparoscopic prostatectomy versus standard robot-assisted laparoscopic prostatectomy for men with localised prostate cancer  (NeuroSAFE PROOF): protocol for a randomised controlled feasibility study. BMJ Open. 2019 Jun 11;9(6):e028132. PMID:31189680

  62. PEOPLE: PatiEnt prOstate samPLes for rEsearch, a tissue collection pathway utilising MRI data to target tumour and benign tissue in fresh radical prostatectomy specimens. Heavey S, .., Shaw G, et al. Prostate. 2019 May;79(7):768-777. PMID: 30807665

  63. C Bailey, RM Bourne, B Siow, EW Johnston, M Appayya.. G L Shaw, A Sridhar, DJ Hawkes, S Punwani, DC Alexander, E Panagiotaki VERDICT MRI validation in fresh and fixed prostate specimens using patient-specific molds for histological and MR alignment. NMR in Biomedicine. In press 2019

  64. Dutto L, Ahmad A, Urbanova K, Wagner C, Schuette A, Addali M, Kelly J.D, Sridhar A, Nathan S, Briggs T.P, Witt J. H, Shaw GL Development and validation of a novel risk score for the detection of insignificant prostate cancer in unscreened patient cohorts. British Journal of Cancer 2018 119, 1445–1450

  65. A. Warren, C. Massie, ..GL. Shaw, .. M Asim Feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene.2018 Sep 20 PMID:30237440. Oncogene, 2018

  66. T. Oliver, P.Wilson, W, Ansell, T, Philp, F. Chinegwundoh, J. Shamash, G Shaw A prospective audit of intermittent anti-androgen verses pituitary blockade suggests a Bipolar Androgen type strategy may be safe in untreated Prostate Cancer. Urol Int. 2017 Dec 22. PMID: 29275414.

  67. AN Sridhar, M Abozaidi, P Rajan, P Sooriakumaran, G Shaw, S Nathan, JD Kelly, T Briggs Surgical Techniques to Optimize Early Urinary Continence Recovery Post Robot Assisted Radical Prostatectomy for Prostate Cancer. Curr Urol Rep (2017) 18: 71 PMID: 28718165

  68. Learning curves for robotic surgery: a review of the recent literature. Mazzon G, Sridhar A, Busuttil G, Thompson J, Nathan S, Briggs T, Kelly J, Shaw GL, Curr Urol Rep. 2017 Sep 23;18(11):89. Review. PubMed PMID: 28942572.

  69. Sridhar AN, Sooriakumaran P, Rajan P, Shaw G, Briggs T, Kelly J, Dasgupta P, Desai M, Wiklund P,Haese A, Montorsi F, Ahmad I, Dutto L, Wagner C, Witt J, Adshead J, Patel V, Nathan S. Corrigendum to “A standard operating technique to facilitate early return of urinary continence after robotic prostatectomy outcomes of a consensus meeting of experts with experience of over 30,000 cases” [Eur Urol Suppl. 2017;16:e2301-2]. Eur Urol Open Sci. 2020 Oct 9;22:1-2. doi: 10.1016/j.euros.2020.09.001. eCollection 2020 Dec.PMID: 34337471.

  70. Asim M. Zecchini HI, Massie CE, Shaw GL,.. Neal DE. Synthetic Lethality between Androgen receptor signaling and PARP pathway in Prostate Cancer. Nat Commun. 2017 Aug 29;8(1):374. PMID: 28851861

  71.  Xu L, Mao X, Guo T, Chan PY, Shaw G, Hines J, Stankiewicz E, Wang Y, Oliver T, Ahmad A, Berney D, Shamash J, Lu YJ. The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis Accepted Clinical Cancer Research 2017 Sep 1;23(17):5112-5122. PMID: 28615267.

  72. Bourne RM, Bailey C, Johnston EW, Pye H, Heavey S, Whitaker H, Siow B, Freeman A, Shaw GL, et al. Apparatus for Histological Validation of In Vivo and Ex Vivo Magnetic Resonance Imaging of the Human Prostate. Front Oncol. 2017 Mar 24;7:47. PubMed PMID: 28393049

  73. Tan W,..Shaw G, Kelly JD Blood Transfusion Requirement and not Preoperative Anaemia is associated with Perioperative Complications following Intracorporeal Robotic Assisted Radical Cystectomy.  J Endourol. 2017 Feb;31(2):141-148. PMID: 27901350.

  74. Johnston T, Shaw GL, Donovan J, Hamdy F, Neal DE, PSA screening improves outcome for men with locally advanced and high risk prostate cancer. Data from the ProtecT trial. European Urology 2017 Mar;71(3):381-388 (In the top 5% of all research outputs scored by Altmetric)

  75. Tan WS, Lamb B, Tan MY, Ahmad I, Sridhar A, Nathan S, Hines J, Shaw G, Briggs T, Kelly J. An in depth critical analysis of complications following robotic assisted radical cystectomy with intracorporeal urinary diversion. Eur Urol Focus. 2017 Apr;3(2-3):273-279. PMID: 28753745.

  76.  Basetti M, Shaw G, Neal D, Warren A, Griffiths J. Response of Degarelix treatment in human prostate cancer monitored by HR-MAS1H NMR spectroscopy. Metabolomics (2016) 12:120 PMID: 27429605

  77. D Thurtle, GL Shaw, V Gnanapragasam. Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a UK regional tertiary referral centre. BJU Int. 2016 Apr 28.PMID 27124625

  78. Shaw GL, Whitaker H, Corcoran M, Warren A, Neal DE, The rapid effects of castration on human prostate cancer. Eur Urol. 2015 Nov 10 PMID: 26572708

  79. Ross-Adams H, Lamb AD, Shaw GL et al. CamCaP Study Group. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and  validation cohort study. EBioMedicine. 2015 Jul 29;2(9):1133-44. PMID: 26501111.

  80. Vasdev N, Agarwal S, Rai BP, Soosainathan A, Shaw G, Chang S, Prasad V, Mohan-S G, Adshead JM. Intraoperative frozen section of the prostate to reduces the risk of positive margin whilst ensuring nerve sparing in patients with Intermediate and high-risk prostate cancer undergoing robotic radical prostatectomy – First Reported UK Series. Curr Urol. 2016 May;9(2):93-103. PMID: 27390582

  81. Asim M, Massie C, Orafidiya F, Shaw G and Neal DE. Choline kinase alpha is an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. J Natl Cancer Inst. 2015 Dec 11;108(5). 2016 May. PMID:26657335

  82. Thomas BC, Kay JD, Menon S, Vowler SL, Dawson SN, Shaw GL, Neal DE, Whitaker HC. Whole blood mRNA in prostate cancer reveals a 4-gene androgen regulated panel. Endocrine related cancer 2016 Oct;23(10):797-812. PMID: 27578825.

  83. Pertega-Gomes N, Vizcaino JR , Felisbino S, Warren AY, Shaw GL, Fryer L, Neal DE and Massie CE. MCT2 protein over-expression throughout prostate cancer progression impacts on oncogenic signaling and malignant phenotypes. Oncotarget 2015 Jun 2. PMID:26035357

  84. Shaw GL, Thomas B, Dawson S, Srivastava G, Vowler S, Gnanapragasam V, Shah N, Warren A, Neal D. Identification of pathologically insignificant prostate cancer is not accurate in unscreened men. Br J Cancer. 2014 May 13;110(10):2405-11. PMID: 24722183

  85. Sooriakumaran P, Srivastava A, Shariat SF, Shaw G, Roobol MJ, Tewari AK Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22,393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. Eur Urol. 2013 Nov 24. PMID: 24290695.

  86. Lewis D, Boren J, Shaw GL, Bielik R, Ramos-Montoya A, Larkin T, Martins C, Neal DE, Soloviev D, Brindle K. Late imaging with [1-11C]acetate PET improves tumour contrast. J Nucl Med. 2014 Apr 28, PMID: 24777291.

  87. A.Ramos-Montoya, A Lamb, R. Russell, V. Theodorou, J. Boren, H.Bon, M.Vias, Shaw GL, N.L Sharma, H.E Scott, SL Vowler, T Carroll, CE Massie, WJ Howat, AY Warren, R. Wooster,I Mills, D.E. Neal. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. EMBO Mol Med. 2014 May 1;6(5):651-61. PMID: 24737870

  88. Shaw GL. Science made simple- Polymorphism- RFLPs and SNPs, BJU International 09/2013; 112(5).

  89. Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL, Performing cytoreductive nephrectomy following targeted Sunitinib therapy for metastatic renal cell carcinoma- a surgical perspective Urol Int. 2012;89(1):83-8.. PMID: 22614181.

  90. Gnanapragasam V, Shaw GL, Mason M, Neal D, Optimal therapy for high risk localised prostate cancer - should surgery be an option or a preferred primary treatment? BJU Int. 2011 Sep 27. doi: 10.1111/j.1464-410X.2011.10596.x. PMID: 21951841

  91. Boyd L, Xue L, Mao X, Li D, Beltran L, Shaw GL, Hines J, Chaplin T, Berney DM, Bryan D. Young BD, Lu YJ. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multi-focal prostate cancer. Genes Chromosomes Cancer. 2012 Jun;51(6):579-89. PMID: 22334418.

  92. Rouse P, Shaw GL, Ahmed H, Freeman A, Allen C, Emberton M. Multi-parametric Magnetic Resonance Imaging to rule-in and rule-out clinically important prostate cancer in men at risk: a cohort study. Urol Int. 2011;87(1):49-53. PMID: 21701136

  93. Vasiljević N, Wu K, Brentnall A, Kim DC, Thorat MA., Kudahetti S, Mao X, Xue L, Yu Y, Shaw GL, Beltran L,. Lu YJ, Berney D, Cuzick J and Lorincz AT.Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer using Pyrosequencing. Dis Markers. 2011;30(4):151-61 2011. PMID: 21694441

  94. Shaw GL, Nair R, Peters J. Minerva, BMJ 2010;341:c3525

  95. Shaw GL, Ioannou I, Gelister J, Briggs T. Management of Vesico Urethral Anastamosis Disruption after Radical Prostatectomy. Urol Int  84, No. 4,  pp 436-439, 2010, PMID: 20224267

  96. Nair R, Holdroyd D, Shaw GL, Gelister J. Reducing false passages: a novel technique for difficult urethral catheterization. Ann R Coll Surg Engl 2010; 92: 259, PMID: 20425888

  97. Tuffaha H, Shaw GL, Briggs T. Augmented bladder appearance under blue light, J Endourol. Journal of Endourology. June 2010, 24(6): 943-944. PMID: 20367243

  98. Dukic I, Shaw GL, Hussein M, Maraj B. A comparison of handwritten to computerised urological operative notes. Brit J. Med Surg Urol..(2010) 3,22-24

  99. Shaw GL  and Bunce C. Fluorescence Cystoscopy- How to do it. Photodiagnosis and Photodynamic Therapy. (2008) 5, 267—270 PMID:19356669

  100. Shaw GL., Emberton M.E, Morgan R,  Berney D., Cuzick J, Oliver R.T.D. Patient designed therapy provides possible “natural” selection evidence for testosterone as differentiating agent for high grade prostate cancer. Brit J. Med Surg Urol. 2009 July 2 (4) 171-173.

  101. Shaw GL and Oliver RTD. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.  J Surg Onc. Mar 2009 PMID:19269165

  102. Ahmed HU, Ishaq A, Zacharakis E, Shaw GL, Illing R, Allen C, Kirkham A,Emberton M. Rectal fistulae after salvage high-intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy. BJU Int. 2008 Nov 18. 321-3 PMID:19021611

  103. Shaw GL and Prowse DM. Inhibition of androgen independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signaling Cancer Cell Int. 2008 Mar 18;8:3. PMID:18348720

  104. Shaw GL, Ktori E, Price AM, Bisson I,  Purkis P, McFaul S, Oliver RTD and  Prowse DM. Hedgehog Signalling in Androgen Independent Prostate Cancer. European Urology 2008 Dec;54(6):1333-43. PMID:18262716

  105. Mao X, Shaw GL, James SY, Purkis P, Kudahett SK, Tsigan T, Kia S, B Young BD, Oliver RTD, Berney D, Prowse DM and Lu YJ. Detection of TMPRSS2:ERG fusion gene in circulating prostate cancer cells. Asian Journal of Andrology 2008 May;10(3):467-73.  PMID:18385909

  106. Shaw GL and Patel HRH. Transdermal Oxybutynin: a review. Expert Opinion in Pharmacology 2007 Jun;3(3):435-9. PMID: 17539749

  107. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry N, Oliver RTD. International study into the use of intermittent therapy in the treatment of carcinoma of the prostate (ISICAP), a meta-analysis of 1446 patients. BJUi 2007 May;99(5):1056-65. PMID: 17346277 Cited as a highlight of Urology. Framingham on Urology. Issue 2 2007

  108. Shaw GL, Purkiss T, Oliver RT, Prowse DM. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its Use as a Diagnostic Test in Prostate Cancer. Eur Urol 2006;50:153-4. PMID:17049717

  109. Shaw GL., Wah TM, Kellett M, Choong S.: Management of renal-vein perforation during a challenging percutaneous nephrolithotomy. J Endourol, 19: 722, 2005 PMID:16053363

  110. Symes A, Shaw GL, Corry, D, Choong S.: Pelvi-calyceal height, a predictor of success when treating lower pole stones with extracorporeal shockwave lithotripsy. Urol Res, 33: 297, 2005 PMID:15937708

  111. Shaw GL, Choong SK, and Fry C.: Encrustation of biomaterials in the urinary tract. Urol Res, 33: 17, 2005  PMID:15614579

  112. Khan MA, Shaw GL, and Paris AM.: Is microscopic haematuria a urological emergency? BJU Int, 90: 355, 2002 PMID 12175388

  113. Martin JE and Shaw GL.: Phenotype analysis in neurological models of human disease. Neuropathol Appl Neurobiol, 24: 83, 1998 PMID 9634201

  114. Jones M, Shaw GL, Roberts G, Sharaf A: Pre-hospital treatment of acute myocardial infarction by GPs: Audit trends,4: 91-94. 1996

Book an appointment

For further advice on urological problems including cancer, please call us on +44 07841034453 to book an appointment, with Mr. Greg Shaw at his private clinic in London. Alternatively, contact us online.

© 2026 Prof Greg Shaw, Consultant Urological Surgeon, London

Book an appointment with Prof Greg Shaw 

Call: 02079359720 or 07841034453

bottom of page